Marshall Wace, LLP Nektar Therapeutics Transaction History

Marshall Wace, LLP

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.49 - $0.96 $448,351 - $878,403	-915,004 Reduced 38.34%	1,471,237 $1.37 Million
Q4 2023 Feb 14, 2024	SELL	$0.42 - $0.57 $230,990 - $313,486	-549,977 Reduced 18.73%	2,386,241 $1.34 Million
Q3 2023 Nov 14, 2023	BUY	$0.51 - $1.05 $1.5 Million - $3.08 Million	2,936,218 New	2,936,218 $1.76 Million
Q1 2023 May 15, 2023	BUY	$0.64 - $3.15 $34,496 - $169,785	53,900 New	53,900 $37,000
Q3 2022 Nov 14, 2022	BUY	$3.04 - $5.14 $94,677 - $160,080	31,144 New	31,144 $100,000
Q1 2022 May 16, 2022	SELL	$4.16 - $13.72 $152,434 - $502,741	-36,643 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$10.83 - $18.41 $564,329 - $959,308	-52,108 Reduced 58.71%	36,643 $495,000
Q2 2021 Aug 13, 2021	BUY	$16.52 - $20.4 $1.47 Million - $1.81 Million	88,751 New	88,751 $1.52 Million
Q1 2020 May 15, 2020	SELL	$14.47 - $27.96 $1.22 Million - $2.36 Million	-84,520 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$15.87 - $23.12 $1.34 Million - $1.95 Million	84,520 New	84,520 $1.83 Million
Q2 2019 Aug 14, 2019	SELL	$31.0 - $36.3 $3.84 Million - $4.49 Million	-123,717 Closed	0 $0
Q1 2019 May 14, 2019	SELL	$31.58 - $46.35 $1.95 Million - $2.87 Million	-61,891 Reduced 33.35%	123,717 $4.16 Million
Q4 2018 Feb 14, 2019	BUY	$30.43 - $56.65 $5.65 Million - $10.5 Million	185,608 New	185,608 $6.1 Million
Q2 2018 Aug 14, 2018	SELL	$46.25 - $104.45 $337,208 - $761,544	-7,291 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$57.4 - $108.44 $418,503 - $790,636	7,291 New	7,291 $775,000

140

135M

32.8K

55.5K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $219M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.